Zoetis Inc. (NYSE:ZTS) Receives $107.43 Consensus Target Price from Analysts

Zoetis Inc. (NYSE:ZTS) has been assigned a consensus recommendation of “Hold” from the nineteen ratings firms that are currently covering the company, Marketbeat reports. Two research analysts have rated the stock with a sell rating, nine have issued a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $101.0769.

ZTS has been the subject of several recent analyst reports. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. TD Cowen cut their target price on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating on the stock in a research note on Tuesday, August 25th. UBS Group reduced their price target on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Stifel Nicolaus decreased their price target on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. Finally, JPMorgan Chase & Co. lowered their price objective on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a report on Friday, August 7th.

Zoetis Trading Up 0.3%

Shares of ZTS opened at $73.05 on Friday. The company has a market capitalization of $30.19 billion, a P/E ratio of 12.03, a P/E/G ratio of 1.70 and a beta of 0.73. Zoetis has a one year low of $71.00 and a one year high of $150.05. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. The stock has a 50-day moving average price of $75.56 and a 200 day moving average price of $91.97.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue for the quarter was down .2% compared to the same quarter last year. During the same period in the previous year, the business earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts forecast that Zoetis will post 6.2 EPS for the current fiscal year.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently made changes to their positions in the company. RFG Advisory LLC raised its holdings in Zoetis by 4.9% in the 4th quarter. RFG Advisory LLC now owns 1,708 shares of the company’s stock valued at $215,000 after buying an additional 80 shares during the period. Financial Engines Advisors L.L.C. boosted its stake in Zoetis by 4.4% during the third quarter. Financial Engines Advisors L.L.C. now owns 2,043 shares of the company’s stock worth $299,000 after buying an additional 87 shares during the period. Physician Wealth Advisors Inc. boosted its stake in Zoetis by 17.4% during the first quarter. Physician Wealth Advisors Inc. now owns 615 shares of the company’s stock worth $73,000 after buying an additional 91 shares during the period. Howland Capital Management LLC increased its position in shares of Zoetis by 4.5% during the second quarter. Howland Capital Management LLC now owns 2,137 shares of the company’s stock valued at $333,000 after acquiring an additional 92 shares during the last quarter. Finally, Smithfield Trust Co increased its position in shares of Zoetis by 4.2% during the fourth quarter. Smithfield Trust Co now owns 2,294 shares of the company’s stock valued at $290,000 after acquiring an additional 92 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors.

Zoetis Company Profile

Zoetis Inc is a global animal health company that develops, manufactures and commercializes medicines, vaccines, diagnostic products and related services for livestock and companion animals. Its offerings are used by veterinarians, livestock producers and pet owners to prevent and treat disease, improve animal health and support productivity.

The company’s product portfolio includes pharmaceuticals, vaccines, parasiticides, dermatology treatments, diagnostic tests and genetic services.